Sugi Predict

Sugi Predict / Compounds / SCHEMBL10240849

SCHEMBL10240849

SCHEMBL10240849

CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc(C(=O)NCCc4ccccc4Cl)cc3)cc12

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 1/20 0.53
▸ CYP3A4 P08684 5/20 0.49
▸ CYP2C8 P10632 5/20 0.49
▸ KCNH2 Q12809 2/20 0.46
▸ NR1I2 O75469 1/20 0.46
▸ CDK4 P11802 1/20 0.46
▸ CCND1 P24385 1/20 0.46
▸ TRPV1 Q8NER1 1/20 0.45
▸ MAPT P10636 1/20 0.44
▸ HTR7 P34969 1/20 0.42
▸ P2RX7 Q99572 1/20 0.42
▸ SNCA P37840 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ SIRT1 Q96EB6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10240646 0.87 MCHR1 (0.53) CYP3A4CYP2C8KCNH2NR1I2SMN1; SMN2
SCHEMBL10240639 0.85 CYP3A4 (0.51) CYP3A4CYP2C8KCNH2NR1I2
SCHEMBL10281023 0.84 CYP2C8 (0.50) CYP3A4CYP2C8KCNH2NR1I2
SCHEMBL10240901 0.83 CYP3A4 (0.49) CYP3A4CYP2C8KCNH2NR1I2
SCHEMBL13457541 0.83 CYP3A4 (0.52) CYP3A4CYP2C8KCNH2NR1I2
SCHEMBL10240784 0.83 CYP3A4 (0.57) CYP3A4CYP2C8KCNH2NR1I2
SCHEMBL10240832 0.83 CYP3A4 (0.49) CYP3A4CYP2C8KCNH2NR1I2
SCHEMBL10240858 0.82 ANO1 (0.54) CYP3A4CYP2C8KCNH2MAPTSMN1; SMN2
SCHEMBL10240892 0.81 CYP3A4 (0.52) CYP3A4CYP2C8KCNH2NR1I2SNCA
SCHEMBL1918184 0.81 CYP3A4 (0.49) CYP3A4CYP2C8KCNH2NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326633-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2015-12-16 — — EP disclosed
US-8722688-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-13 — — US disclosed
US-8722688-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2014-05-13 — — US disclosed
US-20130197012-A1 Compounds for the Treatment of Hepatitis C BRISTOL MYERS SQUIBB CO (US) 2013-08-01 — — US disclosed
US-20130197012-A1 Compounds for the Treatment of Hepatitis C BRISTOL MYERS SQUIBB CO (US) 2013-08-01 — — US disclosed
US-20120316126-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2012-12-13 — — US disclosed
US-20120316126-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2012-12-13 — — US disclosed
US-8309558-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-13 — — US disclosed
US-8309558-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-13 — — US disclosed
US-20120201783-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY 2012-08-09 — — US disclosed
US-8048887-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-01 — — US disclosed
US-8048887-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-11-01 — — US disclosed
US-20110256099-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2011-10-20 — — US disclosed
US-20110256099-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2011-10-20 — — US disclosed
WO-2011112191-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 — — WO disclosed
US-7994171-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-09 — — US disclosed
US-20100249094-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-09-30 — — US disclosed
US-20100093694-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-04-15 — — US disclosed
US-20100093694-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-04-15 — — US disclosed
WO-2010030592-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249094-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HIF1A 4037/4885CYP3A4 299/4885CYP2C8 85/4885
US-20120316126-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HIF1A 4037/4885CYP3A4 299/4885CYP2C8 85/4885
US-20130197012-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HIF1A 4037/4885CYP3A4 299/4885CYP2C8 85/4885
US-20120201783-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C HAVCR2, HCCS, SLC10A1 HIF1A 4037/4885CYP3A4 299/4885CYP2C8 85/4885
US-20100093694-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HIF1A 4037/4885CYP3A4 299/4885CYP2C8 85/4885
US-20110256099-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 HIF1A 4037/4885CYP3A4 299/4885CYP2C8 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.